Issue Date: May 26, 2014
The Next Wave In Rare Disease Funding
When Garmt van Soest was diagnosed with amyotrophic lateral sclerosis, or ALS, a rare and fatal neurodegenerative disease, in August 2013, everyone told him, “Well, that’s it. There’s nothing you can do,” he recalls.
But instead of giving up, van Soest, a consultant at Accenture, decided to put his professional skills to work. After meeting two other European executives with ALS through a patient group, he began thinking about finding a cure. He thought, “Why . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society